OncoMatch/Clinical Trials/NCT07213804
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Is NCT07213804 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for ovarian neoplasms.
Treatment: Sofetabart Mipitecan · Paclitaxel · Topotecan · Gemcitabine · Pegylated liposomal doxorubicin (PLD) · MIRV · Bevacizumab · Carboplatin — This is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whose cancer no longer responds to platinum-based treatments (a type of chemotherapy). Part B looks at participants whose cancer still responds to platinum-based treatments. The researchers want to find out if Sofetabart Mipitecan works better than the usual treatments that doctors use now and to better understand how safe it is. Each participant's time in the study will depend on how they respond to the treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Allowed: BRCA1 mutation
Allowed: BRCA2 mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
relapsed after first-line platinum-based chemotherapy
Must have received: bevacizumab (bevacizumab)
Have received prior bevacizumab treatment, unless documented contraindication or intolerance
Must have received: PARP inhibitor
Have received treatment with a poly(ADP-ribose) polymerase inhibitor (PARPi) if known to have a somatic or germline breast cancer gene (BRCA) mutation, if clinically indicated, unless documented contraindication or intolerance
Must have received: PARP inhibitor
Have previously received a PARPi, per local product label, with progression on, or within 6 months of completion of PARPi treatment
Cannot have received: antibody-drug conjugate
Have received prior antibody-drug conjugate (ADC) with a topoisomerase inhibitor payload
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- HonorHealth · Phoenix, Arizona
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center · Burbank, California
- City of Hope, Duarte · Duarte, California
- Moores Cancer Center · La Jolla, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify